120 related articles for article (PubMed ID: 7532507)
21. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells.
Sieber T; Schoeler D; Ringel F; Pascu M; Schriever F
Br J Haematol; 2003 May; 121(3):458-61. PubMed ID: 12716368
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
23. Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms.
Smith SH; Rigley KP; Callard RE
Immunology; 1991 Jul; 73(3):293-7. PubMed ID: 1715315
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
[TBL] [Abstract][Full Text] [Related]
26. [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
Liu Y; Tang JY; Xu C; Gu LJ; Xue HL; Chen J; Pan C; Dong L; Zhou M
Zhonghua Er Ke Za Zhi; 2009 May; 47(5):366-70. PubMed ID: 19573409
[TBL] [Abstract][Full Text] [Related]
27. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
[TBL] [Abstract][Full Text] [Related]
28. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.
Press OW; Howell-Clark J; Anderson S; Bernstein I
Blood; 1994 Mar; 83(5):1390-7. PubMed ID: 8118040
[TBL] [Abstract][Full Text] [Related]
29. SC3 monoclonal antibody defines a novel specific human B-cell surface antigen differentially expressed on B-cell leukaemias and lymphomas and involved in the proliferation of normal and malignant B lymphocytes.
Nikolova M; Guenova M; Taskov H; Marie-Cardine A; Boumsell L; Bensussan A
Cell Immunol; 2005; 236(1-2):92-100. PubMed ID: 16197933
[TBL] [Abstract][Full Text] [Related]
30. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
31. Antibody-induced antigenic modulation is antigen dependent: characterization of 22 proteins on a malignant human B cell line.
Pesando JM; Hoffman P; Abed M
J Immunol; 1986 Dec; 137(11):3689-95. PubMed ID: 3491146
[TBL] [Abstract][Full Text] [Related]
32. Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma.
Watanabe M; Pesando JM; Hakomori S
Cancer Res; 1990 Jun; 50(11):3245-8. PubMed ID: 1692257
[TBL] [Abstract][Full Text] [Related]
33. Functional effect of IL-7-enhanced CD19 expression on human B cell precursors.
Wolf ML; Weng WK; Stieglbauer KT; Shah N; LeBien TW
J Immunol; 1993 Jul; 151(1):138-48. PubMed ID: 7686930
[TBL] [Abstract][Full Text] [Related]
34. CD19 as an attractive target for antibody-based therapy.
Hammer O
MAbs; 2012; 4(5):571-7. PubMed ID: 22820352
[TBL] [Abstract][Full Text] [Related]
35. Analysis of expression and function of CD40 on normal and leukemic human B cell precursors.
Law CL; Wörmann B; LeBien TW
Leukemia; 1990 Nov; 4(11):732-8. PubMed ID: 1700237
[TBL] [Abstract][Full Text] [Related]
36. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.
Carter RH; Fearon DT
Science; 1992 Apr; 256(5053):105-7. PubMed ID: 1373518
[TBL] [Abstract][Full Text] [Related]
37. Inhibition, by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD19 monoclonal antibodies.
de Rie MA; Zeijlemaker WP; von dem Borne AE
Leuk Res; 1988; 12(2):135-41. PubMed ID: 3282129
[TBL] [Abstract][Full Text] [Related]
38. Induction of isotype switching and Ig production by CD5+ and CD10+ human fetal B cells.
Punnonen J; Aversa GG; Vandekerckhove B; Roncarolo MG; de Vries JE
J Immunol; 1992 Jun; 148(11):3398-404. PubMed ID: 1375243
[TBL] [Abstract][Full Text] [Related]
39. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice.
Rickert RC; Rajewsky K; Roes J
Nature; 1995 Jul; 376(6538):352-5. PubMed ID: 7543183
[TBL] [Abstract][Full Text] [Related]
40. Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest.
Santos-Argumedo L; Gordon J; Heath AW; Howard M
Cell Immunol; 1994 Jul; 156(2):272-85. PubMed ID: 7517793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
